Latrunculin A
Latrunculin A structure
|
Common Name | Latrunculin A | ||
|---|---|---|---|---|
| CAS Number | 76343-93-6 | Molecular Weight | 421.550 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H31NO5S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
Use of Latrunculin ALatrunculin A (LAT-A) is a toxin isolated from the red sea sponge Latrunculia magnifica, binds to actin monomers, inhibits polymerization of actin, with Kds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively[1][2]. |
| Name | latrunculin A |
|---|---|
| Synonym | More Synonyms |
| Description | Latrunculin A (LAT-A) is a toxin isolated from the red sea sponge Latrunculia magnifica, binds to actin monomers, inhibits polymerization of actin, with Kds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Kd: 0.1 μM (ATP-actin), 0.4 μM (ADP-Pi-actin), 4.7 μM (ADP-actin)[2], 0.19 μM (G-actin)[2] |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Molecular Formula | C22H31NO5S |
| Molecular Weight | 421.550 |
| Exact Mass | 421.192291 |
| PSA | 110.16000 |
| LogP | 4.14 |
| Index of Refraction | 1.533 |
| Storage condition | -20℃ |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| Precursor 1 | |
|---|---|
| DownStream 0 | |
CAS#:127733-28-2|
Inhibitory mechanism of FAT4 gene expression in response to actin dynamics during Src-induced carcinogenesis.
PLoS ONE 10(2) , e0118336, (2015) Oncogenic transformation is characterized by morphological changes resulting from alterations in actin dynamics and adhesive activities. Emerging evidence suggests that the protocadherin FAT4 acts as ... |
|
|
Ca(2+) permeation and/or binding to CaV1.1 fine-tunes skeletal muscle Ca(2+) signaling to sustain muscle function.
Skelet. Muscle 5 , 4, (2015) Ca(2+) influx through CaV1.1 is not required for skeletal muscle excitation-contraction coupling, but whether Ca(2+) permeation through CaV1.1 during sustained muscle activity plays a functional role ... |
|
|
Activation of the pleiotropic drug resistance pathway can promote mitochondrial DNA retention by fusion-defective mitochondria in Saccharomyces cerevisiae.
G3 (Bethesda) 4(7) , 1247-58, (2014) Genetic and microscopic approaches using Saccharomyces cerevisiae have identified many proteins that play a role in mitochondrial dynamics, but it is possible that other proteins and pathways that pla... |
| 2-Thiazolidinone,4-((1R,4Z,8E,10Z,12S,15R,17R)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo(13.3.1)nonadeca-4,8,10-trien-17-yl)-,(4R) |
| latrunculin-A |
| Latrunculin A |
| (4R)-4-[(1R,4Z,8E,10Z,12S,15R,17R)-17-Hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]-1,3-thiazolidin-2-one |
| latruculin A |
| (4R)-4-[(1R,4S,5Z,7E,11Z,15R,17R)-17-hydroxy-4,11-dimethyl-13-oxo-14,18-dioxabicyclo[13.3.1]nonadeca-5,7,11-trien-17-yl]-1,3-thiazolidin-2-one |
| 2-Thiazolidinone, 4-((1R,4Z,8E,10Z,12S,15R,17R)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo(13.3.1)nonadeca-4,8,10-trien-17-yl)-, (4R)- |
| latrunculin A (incomplete stereochemistry) |
| 2-Thiazolidinone, 4-[(1R,4Z,8E,10Z,12S,15R,17R)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]-, (4R)- |
| LAT-A |